Brigatinib-5007: A Cohort Study to Describe the Occurrence of Early-Onset Pulmonary Events in Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Treated with Brigatinib: A Post-Authorisation Safety Study First published 26/02/2020 Last updated 06/11/2024 EU PAS number:EUPAS32383 Study Finalised